OBIO Overview

Upcoming Investor Conferences: Orchestra BioMed will participate in the 2025 Jefferies London Healthcare Conference from November 17-20 and the Piper 37th Annual Healthcare Conference from December 2-4, hosting one-on-one meetings and a live fireside chat.

Company Overview: Orchestra BioMed focuses on accelerating high-impact biomedical technologies through partnerships with leading medical device companies, with flagship products AVIM Therapy and Virtue® Sirolimus AngioInfusion™ Balloon currently in pivotal clinical trials.

AVIM Therapy Details: AVIM Therapy is a bioelectronic treatment for hypertension, designed to be delivered via a firmware upgrade to pacemakers, and has received FDA Breakthrough Device Designation for patients with uncontrolled hypertension.

Virtue SAB Overview: The Virtue SAB is a novel drug delivery angioplasty balloon system aimed at treating atherosclerotic artery disease, also granted Breakthrough Device Designation by the FDA for specific coronary and peripheral artery conditions.

Third-Quarter Financial Performance: Orchestra BioMed Holdings, Inc. reported a net loss of $20.8 million or $0.40 per share for the third quarter, an increase from a net loss of $15.4 million or $0.41 per share in the same quarter of 2024.

Revenue Comparison: The company's revenue for the third quarter was $861 thousand, down from $987 thousand in the third quarter of 2024.

Prospectus Filing: Orchestra BioMed filed a prospectus to sell approximately 8.03 million shares by selling stockholders, including shares issued to Covidien Group and Ligand Pharmaceuticals.

Share Breakdown: The prospectus includes about 4.21 million shares from Covidien, 1.81 million from Ligand, and 2 million shares that can be issued upon exercising a warrant with an exercise price of $3.67 per share.

No Proceeds for Company: Orchestra BioMed will not receive any proceeds from the sale of these shares.

Company Updates: The company has seen a rise in stock value as trials for its antihypertensive drug expand, and additional financial information is available through Seeking Alpha’s Quant Rating.